Binding lenalidomide or its analogues, thalidomide and pomalidomide, to CRBN would increase the binding of IKZF1 (Ikaros) and IKZF3 (Aiolos) proteins to the CRBN-based E3ULC, leading to increased ubiquitination and consequent degradation, which is toxic to myeloma cells [11]. The gene discussed is CRBN; the disease is plasma cell myeloma.